Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.

Simon Allison; David Cooke; Francesca S. Davidson; Paul Elliott; Robert Faulkner; Hollie Griffiths; Owen Harper; Omar Hussain; Penelope Owen-Lynch; Roger Phillips; Craig Rice; Samantha Shepherd; Richard T. Wheelhouse

doi:10.1002/anie.201805510

Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.

Simon Allison, David Cooke, Francesca S. Davidson, Paul Elliott, Robert Faulkner, Hollie Griffiths, Owen Harper, Omar Hussain, Penelope Owen-Lynch, Roger Phillips, Craig Rice, Samantha Shepherd, Richard T. Wheelhouse

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

The ligands L1 and L2 both form separable dinuclear double stranded helicate and mesocate complexes with Ru(II). In contrast to clinically approved platinates the helicate isomer of [Ru2(L1)2]4+ was preferentially cytotoxic to isogenic cells (HCT116 p53-/-) which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity with the achiral isomer being preferentially cytotoxic towards HCT116 p53+/+. Other structurally similar Ru(II)-containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be ‘tuned’ to either genotype. In the search for compounds that can target difficult to treat tumours that lack the p53 tumour suppressor gene, [Ru2(L1)2]4+ is a promising compound for further development.

Original language	English
Pages (from-to)	9799-9804
Number of pages	6
Journal	Angewandte Chemie - International Edition
Volume	57
Issue number	31
Early online date	4 Jun 2018
DOIs	https://doi.org/10.1002/anie.201805510
Publication status	Published - 26 Jul 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/anie.201805510Licence: Unspecified

Manu_CRRAccepted author manuscript, 3.75 MBLicence: Unspecified

Cite this

Allison, S., Cooke, D., Davidson, F. S., Elliott, P., Faulkner, R., Griffiths, H., Harper, O., Hussain, O., Owen-Lynch, P., Phillips, R., Rice, C., Shepherd, S., & Wheelhouse, R. T. (2018). Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells. Angewandte Chemie - International Edition, 57(31), 9799-9804. https://doi.org/10.1002/anie.201805510

@article{24506162a4e24ae5bcb6b900d5327920,

title = "Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.",

abstract = "The ligands L1 and L2 both form separable dinuclear double stranded helicate and mesocate complexes with Ru(II). In contrast to clinically approved platinates the helicate isomer of [Ru2(L1)2]4+ was preferentially cytotoxic to isogenic cells (HCT116 p53-/-) which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity with the achiral isomer being preferentially cytotoxic towards HCT116 p53+/+. Other structurally similar Ru(II)-containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be {\textquoteleft}tuned{\textquoteright} to either genotype. In the search for compounds that can target difficult to treat tumours that lack the p53 tumour suppressor gene, [Ru2(L1)2]4+ is a promising compound for further development. ",

keywords = "cancer, cytotoxicity, helicate, mesocate, Ruthenium",

author = "Simon Allison and David Cooke and Davidson, {Francesca S.} and Paul Elliott and Robert Faulkner and Hollie Griffiths and Owen Harper and Omar Hussain and Penelope Owen-Lynch and Roger Phillips and Craig Rice and Samantha Shepherd and Wheelhouse, {Richard T.}",

year = "2018",

month = jul,

day = "26",

doi = "10.1002/anie.201805510",

language = "English",

volume = "57",

pages = "9799--9804",

journal = "Angewandte Chemie - International Edition",

issn = "1433-7851",

publisher = "John Wiley and Sons Ltd",

number = "31",

}

Allison, S , Cooke, D, Davidson, FS, Elliott, P, Faulkner, R, Griffiths, H, Harper, O, Hussain, O, Owen-Lynch, P , Phillips, R , Rice, C, Shepherd, S & Wheelhouse, RT 2018, 'Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.', Angewandte Chemie - International Edition, vol. 57, no. 31, pp. 9799-9804. https://doi.org/10.1002/anie.201805510

TY - JOUR

T1 - Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.

AU - Allison, Simon

AU - Cooke, David

AU - Davidson, Francesca S.

AU - Elliott, Paul

AU - Faulkner, Robert

AU - Griffiths, Hollie

AU - Harper, Owen

AU - Hussain, Omar

AU - Owen-Lynch, Penelope

AU - Phillips, Roger

AU - Rice, Craig

AU - Shepherd, Samantha

AU - Wheelhouse, Richard T.

PY - 2018/7/26

Y1 - 2018/7/26

N2 - The ligands L1 and L2 both form separable dinuclear double stranded helicate and mesocate complexes with Ru(II). In contrast to clinically approved platinates the helicate isomer of [Ru2(L1)2]4+ was preferentially cytotoxic to isogenic cells (HCT116 p53-/-) which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity with the achiral isomer being preferentially cytotoxic towards HCT116 p53+/+. Other structurally similar Ru(II)-containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be ‘tuned’ to either genotype. In the search for compounds that can target difficult to treat tumours that lack the p53 tumour suppressor gene, [Ru2(L1)2]4+ is a promising compound for further development.

AB - The ligands L1 and L2 both form separable dinuclear double stranded helicate and mesocate complexes with Ru(II). In contrast to clinically approved platinates the helicate isomer of [Ru2(L1)2]4+ was preferentially cytotoxic to isogenic cells (HCT116 p53-/-) which lack the critical tumour suppressor gene. The mesocate isomer shows the reverse selectivity with the achiral isomer being preferentially cytotoxic towards HCT116 p53+/+. Other structurally similar Ru(II)-containing dinuclear complexes showed very little cytotoxic activity. This study demonstrates that alterations in ligand or isomer can have profound effects on cytotoxicity towards cancer cells of different p53 status and suggests that selectivity can be ‘tuned’ to either genotype. In the search for compounds that can target difficult to treat tumours that lack the p53 tumour suppressor gene, [Ru2(L1)2]4+ is a promising compound for further development.

KW - cancer

KW - cytotoxicity

KW - helicate

KW - mesocate

KW - Ruthenium

UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050477941&doi=10.1002%2fanie.201805510&partnerID=40&md5=1ed5bdb5dd2e2e536593d7f01bfcd7ac

U2 - 10.1002/anie.201805510

DO - 10.1002/anie.201805510

M3 - Article

VL - 57

SP - 9799

EP - 9804

JO - Angewandte Chemie - International Edition

JF - Angewandte Chemie - International Edition

SN - 1433-7851

IS - 31

ER -

Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Jane Owen-Lynch

Roger Phillips

Craig Rice

Cite this

Ruthenium-containing Linear Helicates and Mesocates with Tuneable p53 Selective Cytotoxicity in Colorectal Cancer Cells.

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Profiles

Jane Owen-Lynch

Roger Phillips

Craig Rice

Cite this